Sirona Biochem Corp. (SRBCF)
USD 0.05
(0.0%)
USD 0.05
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 3.54 Million CAD | 229.26% |
| 2022 | 1.07 Million CAD | -22.27% |
| 2021 | 1.38 Million CAD | -33.75% |
| 2020 | 2.08 Million CAD | 1.09% |
| 2019 | 2.06 Million CAD | -31.8% |
| 2018 | 3.03 Million CAD | -7.9% |
| 2017 | 3.29 Million CAD | 110.75% |
| 2016 | 1.56 Million CAD | -34.87% |
| 2015 | 2.39 Million CAD | 46.43% |
| 2014 | 1.63 Million CAD | 31.22% |
| 2013 | 1.24 Million CAD | 27.82% |
| 2012 | 976.42 Thousand CAD | 34.26% |
| 2011 | 727.25 Thousand CAD | 160.52% |
| 2010 | 279.16 Thousand CAD | 444.29% |
| 2009 | 51.28 Thousand CAD | 6.19% |
| 2008 | 48.29 Thousand CAD | -0.87% |
| 2007 | 48.72 Thousand CAD | 0.0% |
| 2006 | - CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q3 | 4.27 Million CAD | 12.74% |
| 2024 Q1 | 3.49 Million CAD | -1.42% |
| 2024 Q2 | 3.79 Million CAD | 8.5% |
| 2023 Q1 | 1.13 Million CAD | 5.15% |
| 2023 Q3 | 2.42 Million CAD | 9.19% |
| 2023 Q2 | 2.22 Million CAD | 96.46% |
| 2023 Q4 | 3.54 Million CAD | 45.97% |
| 2023 FY | 3.54 Million CAD | 229.26% |
| 2022 Q4 | 1.07 Million CAD | 2.45% |
| 2022 Q3 | 1.05 Million CAD | -9.05% |
| 2022 Q1 | 1.23 Million CAD | -10.98% |
| 2022 Q2 | 1.15 Million CAD | -6.29% |
| 2022 FY | 1.07 Million CAD | -22.27% |
| 2021 Q4 | 1.38 Million CAD | -25.84% |
| 2021 FY | 1.38 Million CAD | -33.75% |
| 2021 Q2 | 1.72 Million CAD | -10.84% |
| 2021 Q1 | 1.93 Million CAD | -7.32% |
| 2021 Q3 | 1.86 Million CAD | 8.11% |
| 2020 Q1 | 1.45 Million CAD | -29.65% |
| 2020 FY | 2.08 Million CAD | 1.09% |
| 2020 Q3 | 1.9 Million CAD | 23.63% |
| 2020 Q2 | 1.54 Million CAD | 6.17% |
| 2020 Q4 | 2.08 Million CAD | 9.48% |
| 2019 FY | 2.06 Million CAD | -31.8% |
| 2019 Q4 | 2.06 Million CAD | -3.64% |
| 2019 Q2 | 2.61 Million CAD | -20.9% |
| 2019 Q1 | 3.31 Million CAD | 9.25% |
| 2019 Q3 | 2.14 Million CAD | -18.1% |
| 2018 Q4 | 3.03 Million CAD | -18.43% |
| 2018 FY | 3.03 Million CAD | -7.9% |
| 2018 Q3 | 3.71 Million CAD | 9.55% |
| 2018 Q2 | 3.39 Million CAD | 5.61% |
| 2018 Q1 | 3.21 Million CAD | -2.41% |
| 2017 Q2 | 2.37 Million CAD | 36.36% |
| 2017 Q1 | 1.74 Million CAD | 11.73% |
| 2017 Q3 | 2.88 Million CAD | 21.18% |
| 2017 FY | 3.29 Million CAD | 110.75% |
| 2017 Q4 | 3.29 Million CAD | 14.15% |
| 2016 FY | 1.56 Million CAD | -34.87% |
| 2016 Q2 | 1.66 Million CAD | -10.4% |
| 2016 Q3 | 1.88 Million CAD | 13.41% |
| 2016 Q1 | 1.85 Million CAD | -22.53% |
| 2016 Q4 | 1.56 Million CAD | -17.26% |
| 2015 Q4 | 2.39 Million CAD | 12.79% |
| 2015 FY | 2.39 Million CAD | 46.43% |
| 2015 Q3 | 2.12 Million CAD | -9.92% |
| 2015 Q2 | 2.36 Million CAD | -5.23% |
| 2015 Q1 | 2.49 Million CAD | 52.09% |
| 2014 Q3 | 1.52 Million CAD | 12.47% |
| 2014 Q2 | 1.35 Million CAD | -9.89% |
| 2014 Q4 | 1.63 Million CAD | 7.29% |
| 2014 FY | 1.63 Million CAD | 31.22% |
| 2014 Q1 | 1.5 Million CAD | 20.67% |
| 2013 Q4 | 1.24 Million CAD | -1.42% |
| 2013 Q3 | 1.26 Million CAD | -8.75% |
| 2013 Q2 | 1.38 Million CAD | -6.74% |
| 2013 Q1 | 1.48 Million CAD | 52.36% |
| 2013 FY | 1.24 Million CAD | 27.82% |
| 2012 Q2 | 825.95 Thousand CAD | 7.89% |
| 2012 Q4 | 976.42 Thousand CAD | 25.28% |
| 2012 Q3 | 779.38 Thousand CAD | -5.64% |
| 2012 Q1 | 765.54 Thousand CAD | 5.26% |
| 2012 FY | 976.42 Thousand CAD | 34.26% |
| 2011 FY | 727.25 Thousand CAD | 160.52% |
| 2011 Q4 | 727.25 Thousand CAD | 104.02% |
| 2011 Q3 | 356.46 Thousand CAD | -20.67% |
| 2011 Q1 | 262.08 Thousand CAD | -6.12% |
| 2011 Q2 | 449.36 Thousand CAD | 71.46% |
| 2010 Q1 | 100.09 Thousand CAD | 95.16% |
| 2010 FY | 279.16 Thousand CAD | 444.29% |
| 2010 Q4 | 279.16 Thousand CAD | 245.12% |
| 2010 Q3 | 80.88 Thousand CAD | 27.66% |
| 2010 Q2 | 63.36 Thousand CAD | -36.7% |
| 2009 Q1 | 101.47 Thousand CAD | 110.09% |
| 2009 Q3 | 44.65 Thousand CAD | 0.0% |
| 2009 Q4 | 51.28 Thousand CAD | 14.85% |
| 2009 FY | 51.28 Thousand CAD | 6.19% |
| 2008 Q3 | 7878.00 CAD | -52.73% |
| 2008 FY | 48.29 Thousand CAD | -0.87% |
| 2008 Q2 | 16.66 Thousand CAD | -19.85% |
| 2008 Q1 | 20.79 Thousand CAD | -57.33% |
| 2008 Q4 | 48.29 Thousand CAD | 513.09% |
| 2007 Q1 | 21.91 Thousand CAD | 0.0% |
| 2007 FY | 48.72 Thousand CAD | 0.0% |
| 2007 Q3 | 20.53 Thousand CAD | -9.07% |
| 2007 Q4 | 48.72 Thousand CAD | 137.3% |
| 2007 Q2 | 22.58 Thousand CAD | 3.05% |
| 2006 FY | - CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 53.3 Million USD | 93.353% |
| Nanobac Pharmaceuticals, Incorporated | 9.58 Million USD | 63.02% |
| SQZ Biotechnologies Company | 50.03 Million USD | 92.919% |
| Evofem Biosciences, Inc. | 72.47 Million USD | 95.111% |
| Santhera Pharmaceuticals Holding AG | 59.01 Million USD | 93.996% |
| Mesoblast Limited | 188.44 Million USD | 98.12% |
| Propanc Biopharma, Inc. | 3.85 Million USD | 7.997% |
| Genus plc | 485 Million USD | 99.269% |
| VioQuest Pharmaceuticals, Inc. | 5.84 Million USD | 39.352% |
| CNBX Pharmaceuticals Inc. | 2.51 Million USD | -40.818% |
| Marizyme, Inc. | 26.67 Million USD | 86.717% |
| ContraFect Corporation | 32.53 Million USD | 89.108% |
| Nymox Pharmaceutical Corporation | 3.8 Million USD | 6.752% |
| PsyBio Therapeutics Corp. | 1.98 Million USD | -78.843% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 3.82 Million USD | 7.425% |
| Intellipharmaceutics International Inc. | 12 Million USD | 70.493% |
| AXIM Biotechnologies, Inc. | 11.77 Million USD | 69.915% |
| MultiCell Technologies, Inc. | 1617.67 USD | -218945.788% |
| Accustem Sciences Inc. | 1.07 Million USD | -228.327% |
| RVL Pharmaceuticals plc | 77.41 Million USD | 95.423% |
| EV Biologics, Inc. | 2.11 Million USD | -67.533% |
| Q BioMed Inc. | 8.13 Million USD | 56.431% |
| Emmaus Life Sciences, Inc. | 82.93 Million USD | 95.727% |
| Neon Bloom, Inc. | 1.22 Million USD | -188.974% |
| Mosaic ImmunoEngineering Inc. | 5.14 Million USD | 31.142% |
| Biomind Labs Inc. | 1.49 Million USD | -136.448% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 244.07 Million USD | 98.548% |
| Oncotelic Therapeutics, Inc. | 18.4 Million USD | 80.746% |
| Skye Bioscience, Inc. | 14.07 Million USD | 74.82% |
| Therapeutic Solutions International, Inc. | 2.01 Million USD | -76.279% |
| THC Farmaceuticals, Inc. | 142.09 Thousand USD | -2393.711% |
| Arch Therapeutics, Inc. | 9.46 Million USD | 62.566% |
| IMV Inc. | 37.93 Million USD | 90.659% |
| Acro Biomedical Co., Ltd. | 201.11 Thousand USD | -1661.888% |
| Curative Biotechnology, Inc. | 5.74 Million USD | 38.33% |
| GB Sciences, Inc. | 5.41 Million USD | 34.593% |
| Alpha Cognition Inc. | 7.16 Million USD | 50.544% |
| HST Global, Inc. | 593.59 Thousand USD | -496.947% |
| CSL Limited | 18.62 Billion USD | 99.981% |
| Halberd Corporation | 728.71 Thousand USD | -386.256% |
| Enzolytics Inc. | 365.26 Million USD | 99.03% |
| Resverlogix Corp. | 67.39 Million USD | 94.742% |
| Affymax, Inc. | 8.87 Million USD | 60.056% |
| SYBLEU INC | 681.41 Thousand USD | -420.013% |
| Nuo Therapeutics, Inc. | 838.73 Thousand USD | -322.476% |
| argenx SE | 444.95 Million USD | 99.204% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 74.92 Million USD | 95.27% |
| Enzon Pharmaceuticals, Inc. | 1.71 Million USD | -106.735% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 11.9 Million USD | 70.231% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | 3.66 Million USD | 3.321% |
| AVAX Technologies, Inc. | 3.99 Million USD | 11.275% |
| Zenith Capital Corp. | 27.56 Thousand USD | -12752.98% |
| Genscript Biotech Corporation | 1.32 Billion USD | 99.733% |
| Ember Therapeutics, Inc. | 238.65 Thousand USD | -1384.76% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 3.73 Million USD | 5.111% |
| WPD Pharmaceuticals Inc. | 680.83 Thousand USD | -420.456% |
| American Oriental Bioengineering, Inc. | 118.72 Million USD | 97.015% |
| Provectus Biopharmaceuticals, Inc. | 9.04 Million USD | 60.812% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | 66.92 Thousand USD | -5194.324% |
| GlobeStar Therapeutics Corporation | 1.43 Million USD | -147.126% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 50.26 Million USD | 92.95% |
| Cotinga Pharmaceuticals Inc. | 2.71 Million USD | -30.675% |
| BioStem Technologies, Inc. | 15.9 Million USD | 77.721% |
| ONE Bio Corp. | 27.49 Million USD | 87.113% |
| Reve Technologies, Inc. | 464.69 Thousand USD | -662.523% |
| Burzynski Research Institute, Inc. | 27.43 Thousand USD | -12816.699% |
| Wesana Health Holdings Inc. | 1.25 Million USD | -181.405% |
| Agentix Corp. | 2.51 Million USD | -41.142% |
| LadRx Corporation | 2.2 Million USD | -61.027% |
| Cell Source, Inc. | 15.8 Million USD | 77.583% |
| ProtoKinetix, Incorporated | 44.69 Thousand USD | -7827.864% |
| Regen BioPharma, Inc. | 5.45 Million USD | 35.074% |
| Regen BioPharma, Inc. | 5.45 Million USD | 35.074% |
| NovAccess Global Inc. | 7.86 Million USD | 54.922% |
| Endonovo Therapeutics, Inc. | 24.74 Million USD | 85.681% |
| Itoco Inc. | 1.65 Million USD | -114.344% |
| Rasna Therapeutics, Inc. | 2.05 Million USD | -72.719% |
| Pathfinder Cell Therapy, Inc. | 6.04 Million USD | 41.421% |
| Kadimastem Ltd | 3.5 Million USD | -1.1% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 421.56 Thousand USD | -740.538% |
| CytoDyn Inc. | 127.89 Million USD | 97.229% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | 41.79 Thousand USD | -8377.327% |
| Mobile Lads Corp. | 1.31 Million USD | -169.771% |
| NanoSphere Health Sciences Inc. | 1.56 Million USD | -126.219% |
| Qrons Inc. | 1.48 Million USD | -138.02% |
| Alseres Pharmaceuticals, Inc. | 11.04 Million USD | 67.919% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 808.79 Thousand USD | -338.114% |
| Rebus Holdings, Inc. | 5.24 Million USD | 32.403% |
| ImmunoCellular Therapeutics, Ltd. | 6.1 Million USD | 41.929% |
| International Stem Cell Corporation | 5.27 Million USD | 32.851% |
| Bioxytran, Inc. | 3.24 Million USD | -9.046% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 625.8 Thousand USD | -466.217% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 4.61 Million USD | 23.254% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 40.99 Million USD | 91.357% |
| Adhera Therapeutics, Inc. | 22.26 Million USD | 84.085% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 2.02 Million USD | -74.951% |
| Innovation Pharmaceuticals Inc. | 5.47 Million USD | 35.315% |
| Neutra Corp. | 973.52 Thousand USD | -263.979% |
| Windtree Therapeutics, Inc. | 29.01 Million USD | 87.788% |
| PureTech Health plc | 125.58 Million USD | 97.178% |
| Coeptis Therapeutics, Inc. | 3.75 Million USD | 5.688% |
| IXICO plc | 1.9 Million USD | -86.468% |
| IntelGenx Technologies Corp. | 20.52 Million USD | 82.739% |
| Gelesis Holdings, Inc. | 103.32 Million USD | 96.571% |
| CSL Limited | 18.62 Billion USD | 99.981% |
| Cellectis S.A. | 249.36 Million USD | 98.579% |